CHMP Recommends EU Approval for Updated Libtayo Dosing Regimen

Key Facts

1The Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for an updated Libtayo dosing regimen in the EU.

2The proposed update allows reducing dosing frequency from every three weeks to every six weeks after the first 12 weeks of treatment.

The Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for an updated Libtayo dosing regimen in the European Union. GlobeNewswire reported that the proposed update allows for a reduction in dosing frequency from every three weeks to every six weeks following the initial 12 weeks of treatment.

The recommendation by the European Medicines Agency's committee aims to provide increased flexibility for patients and healthcare providers by extending the dosing interval. This update covers all approved cancer indications for Libtayo (cemiplimab) within the EU, supporting more efficient treatment management.